Shares of Selecta Biosciences Inc (NASDAQ:SELB) have received an average rating of “Hold” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $8.40.
A number of brokerages have recently issued reports on SELB. Zacks Investment Research upgraded General Moly from a “sell” rating to a “hold” rating in a research report on Thursday. Canaccord Genuity set a $40.00 target price on Mallinckrodt and gave the company a “buy” rating in a research report on Monday, March 18th. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Finally, Mizuho set a $88.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Friday, May 10th.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC raised its stake in Selecta Biosciences by 87.6% in the 4th quarter. Barclays PLC now owns 12,661 shares of the company’s stock valued at $34,000 after purchasing an additional 5,911 shares during the last quarter. Rhumbline Advisers raised its stake in Selecta Biosciences by 50.3% in the 4th quarter. Rhumbline Advisers now owns 23,802 shares of the company’s stock valued at $63,000 after purchasing an additional 7,965 shares during the last quarter. Two Sigma Advisers LP raised its stake in Selecta Biosciences by 18.3% in the 4th quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock valued at $146,000 after purchasing an additional 8,500 shares during the last quarter. Deutsche Bank AG raised its stake in Selecta Biosciences by 251.6% in the 4th quarter. Deutsche Bank AG now owns 127,121 shares of the company’s stock valued at $337,000 after purchasing an additional 90,970 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Selecta Biosciences by 17.9% in the 4th quarter. Geode Capital Management LLC now owns 175,308 shares of the company’s stock valued at $466,000 after purchasing an additional 26,568 shares during the last quarter. 47.07% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:SELB opened at $1.66 on Thursday. Selecta Biosciences has a 1 year low of $1.41 and a 1 year high of $16.55. The company’s 50 day simple moving average is $2.00.
Selecta Biosciences (NASDAQ:SELB) last announced its earnings results on Thursday, May 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.06. The business had revenue of $0.01 million for the quarter. As a group, analysts expect that Selecta Biosciences will post -1.35 earnings per share for the current fiscal year.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Further Reading: What is the Fibonacci sequence?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.